Cancer cells can develop resistance to cytarabine through several mechanisms. These include increased expression of drug efflux pumps like P-glycoprotein, which expel the drug from the cells, and alterations in the enzymes involved in drug activation and metabolism. Understanding these resistance pathways is vital for developing strategies to overcome treatment failure.
